Back to Search Start Over

Discovery of potential WEE1 inhibitors via hybrid virtual screening.

Authors :
Jin T
Xu W
Chen R
Shen L
Gao J
Xu L
Chi X
Lin N
Zhou L
Shen Z
Zhang B
Source :
Frontiers in pharmacology [Front Pharmacol] 2023 Dec 07; Vol. 14, pp. 1298245. Date of Electronic Publication: 2023 Dec 07 (Print Publication: 2023).
Publication Year :
2023

Abstract

G <subscript>2</subscript> /M cell cycle checkpoint protein WEE1 kinase is a promising target for inhibiting tumor growth. Although various WEE1 inhibitors have entered clinical investigations, their therapeutic efficacy and safety profile remain unsatisfactory. In this study, we employed a comprehensive virtual screening workflow, which included Schrödinger-Glide molecular docking at different precision levels, as well as the utilization of tools such as MM/GBSA and Deepdock to predict the binding affinity between targets and ligands, in order to identify potential WEE1 inhibitors. Out of ten molecules screened, 50% of these molecules exhibited strong inhibitory activity against WEE1. Among them, compounds 4 and 5 showed excellent inhibitory activity with IC <subscript>50</subscript> values of 1.069 and 3.77 nM respectively, which was comparable to AZD1775. Further investigations revealed that compound 4 displayed significant anti-proliferative effects in A549, PC9, and HuH-7 cells and could also induce apoptosis and G1 phase arrest in PC9 cells. Additionally, molecular dynamics simulations unveiled the binding details of compound 4 with WEE1, notably the crucial hydrogen bond interactions formed with Cys379. In summary, this comprehensive virtual screening workflow, combined with in vitro testing and computational modeling, holds significant importance in the development of promising WEE1 inhibitors.<br />Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.<br /> (Copyright © 2023 Jin, Xu, Chen, Shen, Gao, Xu, Chi, Lin, Zhou, Shen and Zhang.)

Details

Language :
English
ISSN :
1663-9812
Volume :
14
Database :
MEDLINE
Journal :
Frontiers in pharmacology
Publication Type :
Academic Journal
Accession number :
38143493
Full Text :
https://doi.org/10.3389/fphar.2023.1298245